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Abstract: The aim of this review is to summarize the historical background of drug resistance of 
Gram-positive pathogens as well as to describe in detail the novel lipopeptide antibiotic daptomycin. 
Pharmacological  and  pharmacokinetic  aspects  are  reviewed  and  the  current  clinical  use  of 
daptomycin is presented. Daptomycin seems to be a reliable drug in the treatment of complicated 
skin and skin structure infections, infective right-sided endocarditis, and bacteremia caused by 
Gram-positive agents. Its unique mechanism of action and its low resistance profile, together with 
its rapid bactericidal action make it a favorable alternative to vancomycin in multi-drug resistant 
cocci. The role of daptomycin in the treatment of prosthetic material infections, osteomyelitis, and 
urogenital infections needs to be evaluated in randomized clinical trials.
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Introduction
Gram-positive pathogens have been a challenge to physicians throughout the history 
of medicine. Multi-drug resistance is an emerging threat in the treatment of in- and 
outpatient infections caused by staphylococci, streptococci and enterococci.1 Growing 
interest in safe and effective antibiotics for the treatment of infections related to 
resistant Gram-positive bacteria has led to the development and marketing of new 
substances in recent years, eg, linezolid, tigecyclin, quinupristin-dalfopristin, reta-
pamulin, and daptomycin. This last drug, a lipopeptide antibiotic, has already been 
successfully used in the on- and off-label treatment of severe Gram-positive bacterial 
infections including multi-drug resistant pathogens. Daptomycin, the first-in-class 
cyclic lipopeptide antibiotic, was approved in Europe for the treatment of complicated 
skin and soft tissue infections in 2006 and for the treatment of right-sided infective 
endocarditis due to Staphylococcus aureus and S. aureus bacteremia in 2007.2
The aim of this review is to summarize daptomycin’s unique pharmacological and 
pharmacokinetic properties, its clinical application, and its significance for the treat-
ment of multi-drug resistant pathogens. Detailed information about experimental data 
on microbiological and pharmacological aspects is beyond the scope of this review, 
but may be easily found elsewhere.3
History of drugs and drug-resistance in the 
treatment of Gram-positive microbes
The clinical discovery and early development of penicillin (1928–1940) was a break-
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skin-structure infections (cSSSIs), pneumonia, and others).4 
The first penicillin-resistant cocci were found already in 
1944 and the mechanism of penicillinases was detected.5 
In 1956 methicillin was introduced into clinical practice 
and only two years later the first methicillin-resistant strain 
of S. aureus (MRSA) had been isolated.6 Since then, the 
prevalence of MRSA and methicillin-resistant Staphy-
lococcus epidermidis has steadily increased. In a recent 
study from the US including 422 emergency department 
patients, 59% of S. aureus isolates from skin and soft tis-
sue infections were resistant to methicillin, with variations 
from 20% to 72%.7
The prevalence of community acquired-MRSA is not 
uniform in Europe. It ranges from low in France (3.6% of 
MRSA) and in England, and Wales8,9 to high in Greece, with 
75% of MRSA strains in the community.10 The prevalence 
is also high in Algeria, with 72% of the isolates being 
MRSA.11 Whereas in 1995 less than 40% of all infections 
in North-American intensive care units (ICU) were due 
to MRSA, it was more than 60% in 2004.12 In the same 
year 22.6% of all isolates of S. aureus in Germany were 
MRSA.
Vancomycin, a tricyclic glycopeptide produced by 
Streptomyces orientalis, was discovered in 1956 and 
has been the drug of choice for decades in the treatment 
of patients with MRSA infections.13 Vancomycin is an 
antibiotic with a number of limitations, beginning with 
limited levels in many kinds of tissue and numerous 
side-effects, like nephro- and ototoxicity. Rapid infusion 
(,10 min) may lead to the “red-man-syndrome”, by libera-
tion of huge amounts of histamine.14 Furthermore, Von Dry-
galski et al found vancomycin to be able to cause immune 
thrombocytopenia by induction of auto-antibodies.15 Correct 
dosage of vancomycin is difficult and many authors rec-
ommend drug monitoring. Recent data seem to show that 
continuous infusion of vancomycin may be the best mode 
of application in patients suffering from acute renal failure, 
requiring hemofiltration in an ICU setting.16–18 The minimum 
inhibitory concentration of vancomycin has risen in the last 
decade and consequently the susceptibility break points have 
been lowered.19 In 1996 the first vancomycin (glycopeptides) 
intermediate susceptible S. aureus (VISA) (interchangeably 
GISA) was described and in the first vancomycin-resistant 
S. aureus (VRSA) was detected.20 Since the use of vanco-
mycin has steadily increased in the following decades,21 the 
necessity towards newer antibiotics with bactericidal effects 
upon these pathogens and a more favorable profile of side 
effects has grown.
Linezolid is the first marketed antibiotic of the oxazolidinone 
class with demonstrated activity against   antibiotic-susceptible 
and antibiotic-resistant aerobic Gram-positive cocci, including 
MRSA, methicillin-resistant coagulase-negative staphylococci, 
VRSA, and vancomycin-resistant enterococci. Development 
of linezolid was an important addition to the armamentarium 
of infectious disease specialists in response to the increasing 
prevalence of multiple drug-resistant (MDR) Gram-positive 
pathogens. The possibility of oral administration is a further 
advantage of linezolid. However, some known side effects, eg, 
bone marrow depression, limit the use of linezolid to high-risk 
patients, eg, after solid organ transplantation.
In this context, the in vitro data on drug resistance for 
daptomycin are promising. Silverman et al found a spontaneous 
rate of resistance for S. aureus of ,10−10, and for S. epider-
midis, Enterococcus faecalis, Enterococcus faecium and 
Streptococcus pneumoniae of ,10−9.22 Since its use in the 
clinical practice in 2003, more than 120,000 patients have 
received daptomycin and there have been about 13 cases 
documented in which resistances could be identified.23 In cases 
of reduced susceptibility, combination with other antimicrobial 
drugs (ie, gentamycin or rifampicin) may be advantageous.24 In 
most of these the focus of infection could not be eradicated.
Chemical and historical  
aspects of daptomycin
Daptomycin (LY 146032) is a cyclic lipopeptide, derived from 
a fermentation product of Streptomyces roseoporus. It consists 
of a 13-member amino acid cyclic lipopeptide (hydrophilic 
core) with a decanoyl side chain (lipophilic tail).
The drug was first discovered in the 1980s. The initial trials 
dealt with a dose of 4 mg twice daily and had to be stopped in 
1991 because of frequent elevations of serum levels of creatine 
kinase (CK) probably related to skeletal muscle toxicity.25 In 
1999 the drug was re-introduced into clinical trials. The FDA 
approved daptomycin for the treatment of cSSSIs at a dose 
of 4 mg/kg daily (preceded by a starting dose of 6 mg/kg/
day) at last in 2003.26,27 In 2006 an additional FDA approval 
was granted for the treatment of bloodstream infections 
and right-sided endocarditis caused by methicillin-sensitive 
S. aureus (MSSA) and MRSA. The approval was confirmed 
in Europe in 2007.
Antibacterial properties  
and pharmacological profile  
of daptomycin
The bactericidal mechanism of daptomycin may be divided 
into two parts. First of all, the lipophilic decanoyl side Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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chain is irreversibly bound and then calcium-dependently 
inserted into the bacterial cell wall without entering the cell’s 
cytoplasm.28 This binding leads to a second reaction consisting 
of a disruption of the cell membrane, followed by a rapid 
potassium efflux with subsequent loss of the ion concentration 
gradient, depolarization of the cell membrane, and a 
subsequent disruption of the production of macromolecules 
like RNA, DNA and other proteins.29,30 Daptomycin exerts 
its bactericidal action in a rapid (,60 min) and concentra-
tion dependent way. The area under the concentration-time 
curve is 747 µg/h/mL at 6 mg/kg and 494 µg/h/mL at 
4 mg/kg dosage IV. The maximal plasma concentration 
(Cmax) is 98.9 µg/mL and 57.8 µg/mL, respectively.31 
A post-antibiotic effect, as known for fluoroquinolones, has 
also been described for daptomycin: dependent on the calcium 
concentration, this effect may last for 0.5 to 6.8 hours in 
staphylococci, enterococci and streptococci, as documented 
in the literature.32,33 The serum half-life of daptomycin is 
8.6 hours at 4 mg/kg/day and 8.1 hours at 6 mg/kg/day. It is 
highly protein-bound (91%–96%) which in combination with 
its inability to cross cell membranes results in a low volume 
of distribution (0.09 l/kg).34,35 Daptomycin is a large molecule 
and therefore cannot pass through the gastrointestinal mucosa. 
Thus, the enteral application is not available. This property 
of daptomycin is a hindrance in terms of clinical application. 
However, this property may limit the non-controlled use of 
daptomycin in the outpatient setting, reducing therefore the 
risks of developing resistance. Daptomycin is excreted mainly 
unchanged in the urine (60%) and therefore the dosing interval 
has to be increased to 48 hours in patients with a creatinine 
clearance below 30 mL/min.36 Daptomycin also shows effi-
cacy against Gram-positive pathogens, including multi-drug 
resistant staphylococci, enterococci, and even VISA and 
vancomycin-resistant enterococcus (VRE) in vitro.
Side effects and safety profile  
of daptomycin
Safety aspects and tolerability have been documented 
in a number of trials. However, many of the observed 
potential side effects (AEs) were not clearly attributable 
to the study medication. The most frequently experienced 
AEs were gastrointestinal disturbances (ie, constipation, 
nausea and vomiting and diarrhea), reactions at the injec-
tion sites and headache. All these effects were observed in 
frequencies similar to the comparator drugs (ie, 3%–6%). 
Musculoskeletal side effects (ie, rise in CK) were the 
cause for termination of the initial studies on daptomycin 
in 1985. Interestingly, this effect is probably due to micro-
scopic degenerations and regenerations of muscle fibers. 
However, as this process does not result in cell lysis and is 
firstly related to the dosing interval, but not to the plasma 
levels of daptomycin or drug accumulation,37 it does not 
seem to be relevant. Of the patients in the daptomycin 
group of the trial by Arbeit et al, 2.8% showed elevated 
levels of CK, all returning to normal within two weeks.38 
Although recent reports emphasize the clinical safety of 
daptomycin, even with doses of more than 6 mg/kg/day,39 
severe rhabdomyolisis may even occur with current dos-
ing regimens.40 In the endocarditis/bacteremia trial, 6.7% 
of the patients in the daptomycin group showed elevated 
levels of CK, which were significantly higher than in the 
comparator group (P = 0.04).41
In the same trial, 9.2% of the patients who received 
daptomycin developed peripheral neurological symptoms 
(ie, paresthesias and dysesthesias) which were significantly 
more common than in the comparator group (1.7%). 
However, all symptoms were classified as mild to moderate 
in severity and most were short-lived and completely revers-
ible despite continued treatment.
Clinical applications of daptomycin
Daptomycin for CSSSIs
Daptomycin received FDA approval for CSSSIs in 
2003 on the basis of two randomized evaluator-blinded 
phase III studies, comparing daptomycin (4 mg/kg/day) 
either to vancomycin (1 g/12 h) or an oxacillin class antibiotic 
(flucloxacillin, cloxacillin, oxacillin or nafcillin at a dose of 
4 to 12 mg/kg/day).27,42,43 Some interesting details may be 
mentioned: In both groups (daptomycin and comparator 
group) about 10% (10% and 9.3%) had infections due to 
MRSA, with S. aureus being the leading cause of infection 
in the whole study population. Daptomycin was shown to be 
safe (no higher incidence of side effects) and effective with 
respect to the kind of infecting agents and the site of infection. 
Furthermore, retrospective data reported in the CORE study 
support the effectiveness and safety of daptomycin in the 
treatment of cSSSI.44
Daptomycin for right-sided  
endocarditis and bacteremia
In 2006 Fowler et al published a randomized controlled 
trial which compared daptomycin to vancomycin or anti-
  staphylococcal penicillins in combination with gentamycin.45 
On the whole, daptomycin and standard treatment were 
equally effective at the end of treatment (61% vs 60.9%) 
and 42 days after the end of treatment (44.2% vs 41.7%). Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Some limitations of the trial may be mentioned. First of 
all, there were more relapsing infections due to S. aureus 
in the daptomycin group (15.8% vs 9.6%; not statistically 
significant). Furthermore, the trial cannot give significant 
information about left-sided endocarditis, as only 18 patients 
with this disease were included. The success rate in this group 
was very low in both study groups. In conclusion, daptomycin 
seems to be a promising alternative to standard therapeutic 
approaches in patients with right-sided endocarditis and 
bacteremia.
Off-label use of daptomycin
Bone and joint infections
Daptomycin was found to be a promising option in the 
therapy of patients presenting with bone and joint infections 
by Falagas et al. They resumed the clinical use of this lipo-
peptide antibiotic in patients with bone and joint infections 
in a systematic review.46 In different case reports, including 
discitis, osteomyelitis, hip and knee infection, septic arthritis, 
as well as different joint inflammatory processes, daptomycin 
proved efficient with an initial full remission of the infection 
of 58%. The decision to switch to daptomycin was taken after 
failure of the administered monotherapy with vancomycin 
alone, or in combination with other antibiotics. MRSA was the 
predominant pathogen (83%) in the cases presented. Some case 
series47–49 documented the safe use of daptomycin in patients 
(n = 53) suffering from bone and joint infections, the principal 
indication being osteomyelitis. In these patients, MRSA was 
again the predominant responsible pathogen (73%) and the 
reported cure of infection after intravenous administration 
of a standard dose of 4–6 mg/kg/day was 81%. Although the 
effective use of daptomycin in joint and bone infections docu-
mented by Falagas et al50 is almost exclusively in orthopedic 
patients, this report must be kept in mind for decision-making 
in heart surgery patients presenting with multi-resistant Gram-
positive infections of the sternotomy wound, which commonly 
originate osteomyelitis and presents almost no other surgical 
alternative.51,52
The successful treatment of prosthetic material with 
daptomycin has also been documented in the literature. 
Antony et al and Carlyn et al reported the use of daptomycin 
in knee prostheses MRSA infection47,53 Furthermore, Cunha 
et al employed daptomycin successfully in the treatment of 
different prosthetic material infections, including MRSA 
infection of a pacemaker54 and a MSSA infection of a 
peripherally inserted central catheter.55 Weis et al reported 
the treatment with daptomycin of a patient presenting with 
a MRSA infection in a biventricular assist device.56 Presterl 
et al reported recently the use of daptomycin in cardiac 
device infections with S. epidermidis.57 Beiras-Fernandez 
et al documented a case series of 8 patients presenting 
with ventricular assisted devices successfully treated with 
daptomycin after multidrug resistant pathogen infection.
Urinary tract infections
Daptomycin presents favorable pharmacokinetics for this 
kind of infection as 66% of the active drug is excreted 
in the urine.58 Furthermore, in vitro data show a good 
activity of daptomycin in comparison to linezolid and 
vancomycin for Gram-positive uropathogens causing 
complicated urinary tract infections. However, these 
promising results have not yet been confirmed by clini-
cal trials.59
Community-acquired pneumonia (CAP)
Daptomycin was ineffective for CAP treatment in two 
phase III non-inferiority trials (cure rate 79% vs 87%)27 
when compared to ceftriaxone. A murine in vitro model 
demonstrated that the pulmonary surfactant acts as a 
scavenger for daptomycin, leading to high levels in the 
epithelial lining fluid, but a low insertion rate into the 
bacterial cell wall.60 Daptomycin inserts preferentially 
into pulmonary surfactant and thus shows a significant 
elevation of the MIC in lungs with rising concentrations 
of surfactant. In patients with hematogeneous pneumonia 
the results might be better.
Left-sided endocarditis
Daptomycin has been approved for use in bacteremia and right-
sided endocarditis in 2007; however, left-sided endocarditis 
therapy remains off-label. Different experimental models 
involving different pathogens such as MRSA, MSSA, Entero-
coccus spp, and VRE for left-sided endocarditis have shown 
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a very promising antimicrobial activity of daptomycin61–64 
Furthermore, Cunha et al and Mergenhagen et al reported 
successful treatment with 6 mg/kg/day daptomycin of MRSA 
left-sided endocarditis.65 Falagas et al performed a systematic 
review of the use of daptomycin in patients presenting with 
endocarditis and included some cases regarding its successful 
use in left-sided endocarditis.66
Although daptomycin proved efficient in some of 
the above stated indications, further clinical evidence in 
form of randomized clinical trials is needed to evaluate 
its effectiveness and safety in osteomyelitis, mediastinitis, 
joint infection,   prosthetic material infections and left-sided 
endocarditis.
experimental data on topical application
Despite the very modest extent of side-effects described for 
daptomycin, experimental use of topical daptomycin has 
been brought forward in recent years.67 Antibiotic-loaded 
bone-cement seems to be the most promising option in this 
field. It seems to be possible to provide sufficient peak and 
sustained concentrations of daptomycin to inhibit bacterial 
growth even in infected bones.68 The clinical relevance of these 
data will have to be proven by randomized controlled trials.
Conclusions
Development of new antibiotics is essential due to 
the increasing incidence of antibiotic drug resistance. 
Daptomycin, a new lipopeptide antibiotic, has proven a 
successful and less toxic alternative to vancomycin in the 
treatment of multidrug resistant Gram-positive pathogens. 
It seems to be a reliable drug in the treatment of cSSSIs, 
infective right-sided endocarditis, and bacteremia caused 
by Gram-positive agents. The role of daptomycin in the 
treatment of prosthetic material infections, mediastinitis, 
osteomyelitis, and urogenital infections needs to be further 
evaluated.
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